 |
PDF »
September 4, 2008
Cougar Biotechnology to Present at Morgan Stanley Global Healthcare Conference
Los Angeles, CA, September 4, 2008 - Cougar Biotechnology, Inc. (NASDAQ: CGRB) today
announced that Alan H. Auerbach, Chief Executive Officer and President of Cougar, will present at the
Morgan Stanley Global Healthcare Unplugged Conference on Tuesday, September 9, at 9:10 a.m. EDT at
the Grand Hyatt in New York City. Mr. Auerbach will provide a company overview and update on the
status of Cougar’s current clinical development programs.
Interested investors may access a live audio webcast by visiting the Investor Relations section of the
Company’s Web site at www.cougarbiotechnology.com. The presentation will be archived on the Web
site and available for 30 days.
About Cougar Biotechnology
Cougar Biotechnology, Inc. is a Los Angeles-based biotechnology company established to in-license and develop clinical stage drugs, with a specific focus on the field of oncology. CougarŐs oncology portfolio includes CB7630, a targeted inhibitor of the 17alpha-hydroxylase/c17,20 lyase enzyme, which is currently being tested in Phase III clinical trials in prostate cancer; CB3304, an inhibitor of microtubule dynamics, which is currently in a Phase I trial in multiple myeloma; and CB1089, an analog of vitamin D, which has been clinically tested in a number of solid tumor types.
Further information about Cougar Biotechnology can be found at www.cougarbiotechnology.com.
Contact
Cougar Biotechnology, Inc.
+1-310-943-8040
Alan H. Auerbach, Chief Executive Officer and President
ahauerbach@cougarbiotechnology.com
Mariann Ohanesian, Director of Investor Relations
mohanesian@cougarbiotechnology.com
Russo Partners, LLC
David Schull, +1-212-845-4271
david.schull@russopartnersllc.com
Andreas Marathovouniotis, +1-212-845-4235
andreas.marathis@russopartnersllc.com
| | |
Cougar Biotechnology, Inc.
10990 Wilshire Blvd, Suite 1200
Los Angeles, CA 90024
(310) 943-8040 Main
(310) 943-8059 Fax |
